An EORTC phase II study of mitoxantrone in solid tumors and lymphomas

Area of Science:

• Medical Oncology
• Pharmacology
• Cancer Research

Background:

• Mitoxantrone is an anthracenedione with structural similarities to doxorubicin.
• It exhibits activity against various tumors, including doxorubicin-resistant types and human breast xenografts.
• Mitoxantrone demonstrates a reduced cardiotoxicity profile compared to doxorubicin.

Purpose of the Study:

• To evaluate the anti-tumoral activity and toxicity of mitoxantrone in patients with advanced malignancies.
• To assess response rates across different cancer types and treatment regimens.
• To compare the efficacy and safety of different mitoxantrone dosages.

Main Methods:

• Intravenous (IV) perfusion of mitoxantrone at 12 mg/m2 or 14 mg/m2 every 3 weeks.
• Evaluation of 263 patients with advanced disease, including breast, head and neck, kidney, bronchial, and lymphomas.
• Patients had received prior radiotherapy and/or chemotherapy, including doxorubicin.

Main Results:

• A 20% response rate (3 CR, 16 PR) in 94 breast cancer patients; higher response in chemotherapy-naive patients (35% vs 15%).
• Higher response rate observed with 14 mg/m2 (32%) compared to 12 mg/m2 (15%); no response in lung metastases.
• Activity in lymphomas (4/13 responses) and borderline activity in head and neck tumors (3/40 responses). Moderate myelosuppression, nausea/vomiting in 50%, cardiac events in 4 patients, and alopecia (17-48%).

Conclusions:

• Mitoxantrone exhibits significant anti-tumoral activity, especially in breast cancer, and is a viable option for patients previously treated with chemotherapy.
• The 14 mg/m2 dosage showed a superior response rate compared to 12 mg/m2.
• Mitoxantrone is considered a major antimitotic agent due to its efficacy and favorable hematological and cardiac toxicity profile.